Logo image
Intracerebroventricular SPAST-AAV9 gene therapy prevents the manifestation of symptoms in a mouse model of SPG4 Hereditary Spastic Paraplegia
Journal article   Open access   Peer reviewed

Intracerebroventricular SPAST-AAV9 gene therapy prevents the manifestation of symptoms in a mouse model of SPG4 Hereditary Spastic Paraplegia

Emanuela Piermarini, Shrobona Guha, Liang Qiang, Heather Gray-Edwards, Miguel Sena-Esteves and Peter W Baas
Molecular therapy, v 34(3), Forthcoming
26 Nov 2025
PMID: 41311060
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC12856983/View
Open

Abstract

Hereditary Spastic Paraplegia type 4 is characterized by gait impairments, progressive spasticity and weakness of the lower limbs, resulting from degeneration of the corticospinal tracts. The disease is caused by mutations of the SPAST gene, which encodes a major isoform of spastin called M87 and a minor isoform called M1. Owing to its N-terminal hydrophobic domain not shared by M87, M1 is the isoform that becomes toxic when mutated. Loss-of-function of either M1 or M87 or both may also play a role in the disease, sensitizing corticospinal motor neurons to the toxicity of mutant M1. Here we pursued silence-and-replace gene therapy, which addresses both gain-of-toxicity and loss-of-function components of the disease. We generated an adeno-associated serotype 9 viral vector containing micro-RNA to stop the expression from the endogenous SPAST gene and cDNA to express healthy human M1 and M87. The vector was introduced by intracerebroventricular injections into newborn pups of SPAST-C448Y, a mouse model of the disease that expresses human mutant spastin and displays adult-onset corticospinal degeneration and gait defects. The treatment successfully replaced both isoforms of endogenous spastin with healthy spastin, at physiological levels, and prevented the onset and progression of corticospinal degeneration and gait defects.

Metrics

12 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Biotechnology & Applied Microbiology
Genetics & Heredity
Medicine, Research & Experimental
Logo image